To assess treatment efficacy in clinical trials, certain clinical outcomes are repeatedly measured over time for the same subject. These outcomes can be regarded as a function of time. The difference in their mean functions between the treatment arms usually characterises a treatment effect. Due to the potential existence of subject-specific treatment effectiveness lag and saturation times, erosion of treatment effect may occur during the observation period. Instead of using ad hoc parametric or purely nonparametric time-varying coefficients in statistical modeling, we first propose to model the treatment effectiveness durations, which are the varying time intervals between the lag and saturation times. Then some mean response models are used to include such treatment effectiveness durations. Our methodologies are demonstrated by simulations and an application to the dataset of a landmark HIV/AIDS clinical trial of short-course nevirapine against mother-to-child HIV vertical transmission during labour and delivery.
Introduction
In clinical trials, repeated measurements of the same subject are often collected during a given period of time to assess the efficacy of a new treatment. Assume that (Y 1 , Y 2 , . . . , Y m ) is the vector of the repeated measurements collected at the time points T 1 < T 2 < . . . < T m , respectively, from the same subject during the time period [0, C] , where C is the potential maximum length of the observation time period. These repeated measurements can be considered as observations of an underlying random response curve over time, {Y (t); t ≥ 0}, with Y (T j ) = Y j , j = 1, 2 . . . , m. Regression models are the main tool used in statistical literature to model the means of these response curves and to identify a treatment effect.
One widely used model for {Y (t); t ≥ 0} was proposed in Zeger & Diggle (1994) and later generalised in Lin & Ying (2001) ,
where Z(·) is the covariate vector of p 1 -dimension, β ∈ p 1 is the associated regression parameter and µ(·) is some baseline function for Z(t) ≡ 0, respectively. Here, T denotes vector transpose. Usually, neither µ(t) nor the error structure of {Y (t), t ≥ 0} has to be specified in (1). Such a semiparametric model setup would usually allow for substantial model flexibility when the treatment efficacy parameter β is of major interest.
In model (1), the constant β serves as a concise summary measure of the difference in the mean responses over time, for example, when Z(t) is a treatment indicator. If the assumption of constant β appears valid, a consistent estimator of β can be used to characterise and make inference on the treatment efficacy. This assumption, however, may be undermined in practice by the phenomenon of 'erosion of regression effect,' as termed in a recent paper
by O'Quigley & Natarajan (2005) on the proportional hazards model of survival outcomes.
For the repeated measurements in model (1), similar erosion phenomenon on the constant β may occur when the treatment effectiveness lag time and the saturation time possibly exist.
Treatment effectiveness lag time is the time after which the treatment becomes fully effective. Its existence has long been noted and studied, for example, in Halperin et al. (1968) , Zucker & Lakatos (1990) and Chen et al. (2002) . Treatment saturation time is the time after which the full treatment effect starts to attenuate or diminish due to reasons such as cumulative buildup of drug resistance (Eshleman et al., 2001; Komarova & Wodarz, 2005; Wu et al., 2005) . The interval between the lag time and the saturation time is thus the treatment effectiveness duration on which the treatment is expected to take full effect.
Because of biological heterogeneity among subjects, the treatment effectiveness durations are not necessarily identical for all subjects. The variation among subjects may lead to the phenomenon of effect erosion, as shown in a later section.
Effect erosion due to varying effectiveness durations is a particular type of departure of the regression parameter from being constant. In the statistical literature, one mathematically convenient approach to handling the effect erosion in model (1) is to allow the regression parameter to be time-varying as β(t) in
similar to that proposed in Hoover et al. (1998) . Here, β(·) can be specified in some ad hoc parametric form. Or, it can be nonparametrically assumed and estimated by various methods, such as smoothing splines and locally weighted polynomials in Hoover et al. (1998) , component-wise smoothing splines in Chiang et al. (2001) and basis function approximation in Huang et al. (2002) . The most practical values of flexible nonparametric β(·) for model (2) in real applications are in, for example, model adequacy assessment or model-based prediction/forecasting. Although it can be used to explore the time-varying pattern in covariate effect, the time-varying coefficient itself may not result in direct summary of treatment effect or lead to straightforward comparison of treatment effects among the clinical trials.
In the rest of this article, we focus on the treatment effect estimation by taking into account the effect erosion due to the possible varying treatment effectiveness durations. Some joint distributions for the bivariate treatment effectiveness lag time and the effectiveness duration are first proposed. The mean response model (1) of the constant β is subsequently extended by allowing changepoints to accommodate the varying treatment effectiveness durations. Inference procedures including hypothesis testing and interval estimation are studied in §3. Numerical studies are presented in §4. Further model extensions are laid out in §5.
Some concluding remarks and discussion are presented in §6.
Statistical Models

Models for treatment effectiveness duration
Let U and V be the possible treatment effectiveness lag and saturation times, respectively, where 0 ≤ U ≤ V , for a subject in the study. Then the time interval [U, V ] is the effectiveness duration. Denote W = V − U the length of the effectiveness duration. Consider the joint density function of the bivariate vectors of (U, W ), f U,W (u, w; θ), for the lag time and the effectiveness duration, where θ is the parameter of p 2 -dimension. When U and W are independent, f U,W (u, w; θ) is simply the product of the marginal density functions, f U (u) and f W (w), say, of U and W , respectively. There are a variety of distributions that can be used for f U (u) and f W (w), such as the exponential, Weibull or Gamma distributions.
In reality, since U and W reflect a human subject's individual reaction to the treatment, they are often not necessarily independent among subjects. In some instances, when a subject has relatively a shorter metabolic cycle, he or she usually responds to the treatment faster and reaches the full effect sooner. At the same time, the treatment's full effect is maintained for a relatively shorter duration of time. On the other hand, when the metabolic cycle tends to be longer, both the treatment lag time and the effectiveness duration tend to be longer. Thus U and W are positively correlated. The shared frailty models (Oakes, 1989) can be then applied to the bivariate times (U, W ).
Assume that G is the subject's underlying frailty, representing the effect of underlying metabolism on U and W simultaneously. Let its density function be f G (g; α), where α is the parameter. Conditional on G, the metabolism affects the hazard functions for U and W by Gλ U (t) and Gλ W (t), respectively. Thus the bivariate survival function of (U, W ) is,
where Λ U (t) = 
As a result,
One widely used family is the Clayton-Oakes model, or the Gamma frailty model (Clayton, 1978; Oakes, 1989) . In this model, G is assumed to follow the Gamma density function,
Therefore, the bivariate density function for (U, W ) is thus
In practice, given the multiplicative form of g on λ U (·) and λ W (·), it is usually sensible to further assume that α 1 = 1/α 2 , which leads to EG ≡ 1.
Mean response models with varying effectiveness durations
Suppose that the covariate vector of Z(t) = (Q(t) T , R(t) T ) T mainly consists of two types of covariates: Q(t) are the covariates that take full effect only on the effectiveness duration, and R(t) are the concomitant variables that are not affected by the effectiveness durations. When the treatment effectiveness duration defined by (U, W ) is known, we consider the following model,
where I(·) is the indicator function, and (β
That is, conditional on (U, W ), the mean response of the repeated measurements is µ(t) + β
Thus the parameter β Q characterises the subject-specific differences in the mean responses associated with Q(t) on the effectiveness duration. When Q(t) is the treatment indicator, β Q represents the subject-specific treatment effect.
This model is indeed a changepoint model with two subject-specific changepoints at U and U + W , respectively. When U = 0 and W = ∞, it reduces to the model in (1). Most of the previous methodological research on changepoint models has focused on the detection of location and magnitude of changepoints, such as in Wu et al. (2001) . The major interest of the current model (3) still lies in the regression parameter of β's, while the changepoints and their distributions serve as nuisance to introduce the phenomenon of time-varying erosion on the regression parameter, as observed in the marginalised version of (3),
with respect to the distribution of (U, W ), where β Q (t) = β Q H(t; θ). Here, H(t; θ) = t 0 ∞ t−u f U,W (u, w; θ)dwdu is the 'erosion operator' that modifies the subject-specific constant regression parameter β Q to the marginal time-varying coefficient β Q (t), due to the varying treatment effectiveness durations of (U, W ). In §4, some specific examples are given to demonstrate the generally U-shaped β Q (·).
In fact, the erosion operator H(·) has the following properties:
The first property mandates that the marginal |β Q (t)| should be no larger than the subjectspecific |β Q |. The second property implies that the treatment efficacy diminishes to null at the beginning of a randomised trial for the short-term and also toward the long-run, which echoes the usual actual observation of regression effect erosion. The third property will allow us to calculate the time point at which H(t) reaches its peak, and the turning points as well when the overall trend of H(t) changes.
It is apparent that the two parameters, namely, the scale parameter of β Q and the shape parameter of θ, jointly determine a specific β Q (·) in the marginalised model (4). When µ (·) is parametric and the error structure of Y (·) is known, both parameters are identifiable in model (4) using the maximum likelihood method. In general, however, when µ(·) is unspecified as in Zeger & Diggle (1994) or the error structure is further unknown as in Lin & Ying (2001) , the parameters are identifiable only up to the function of β Q (·) itself. In the latter semiparametric settings, similar to those in Chen et al. (2002) , it can be shown that the parameter of interest, β Q , is identifiable if and only if the nuisance parameter θ is identifiable. In fact, the parameter θ is only meaningful and identifiable when β Q = 0, as pointed out by Luo et al. (1997) . When β Q = 0, it is usually of less scientific interest to consider either the treatment effectiveness lag or the saturation time. Nevertheless, this is the type of problem discussed in Davies (1977 Davies ( , 1987 , that is, the nuisance parameter θ is present only under the alternative of β Q = 0. In the following sections, we will develop inference procedures by taking this complication into consideration.
Inferences
We first assume in this section that β Q = 0 as in Luo et al. (1997) . Suppose that there are n independent and identically distributed copies of
assumed to be independent. The true parameters hereinafter are denoted by their respective counterparts with the subscript ' * .' For instance, the true parameters for β Q and β R in (3) are β Q * and β R * , respectively. Consider the cumulative sum of the residuals for the ith
Here, dΩ µ (t) = µ(t)dΩ(t).
are unknown in (6), an estimator of the Breslow-type can be obtained for Ω µ (·) by solving
. Therefore, similar to those in Lin & Ying (2001) and Chen & Jewell (2001) , the following estimating equations generalise the normal equations of the least-squares for the linear regression models to estimate the parameters in the proposed model (4),
where ψ i (t) are the known smooth functions of (p 1 + p 2 )-dimension and measurable with respect to σ{Z i (s),
does not belong to the linear span of 1 and Z. For example, G(·) is selected to be some nonlinear transformation of log Z or Z · Z. In fact, straightforward algebra further leads to
where
Assume that β and θ are the solutions of β and θ in (7), respectively.
Let ν i (t) be the derivative of ν i (t), i = 1, 2, . . . , n. Then −n −1 E (β * , θ * ) goes to
where ψ * (t) is the limit of ψ(t) almost surely, as n → ∞. When f U,W (u, w) degenerates to 1 at (u, w) = (0, ∞) and 0 otherwise, and ψ i (·) are chosen to be Z i (·), the proposed model Thus as shown in the Appendix, the solutions to E (β, θ) = 0 are strongly consistent under mild conditions as n → ∞. If the total variation of ψ i (·), i = 1, 2, . . . , n, are bounded, it is then true that
By the Central Limit Theorem, it is also shown in the Appendix that n −1/2 E (β * , θ * ) is asymptotically normal with mean zero and the variance-covariance matrix,
where a ⊗2 denotes aa T . In addition, a Taylor's expansion of E ( β, θ) at (β * , θ * ) yields that
Therefore, β and θ are consistent, and
bution in a neighbourhood of (β * , θ * ), where D and Σ can be approximated by their empirical
To estimate the baseline µ(·), consider the estimator of µ(t) = Y (t) − ν(t; β, θ), where
, respectively. When the observation times are observed in a continuous time scale, some smoothing technique has to be implemented to obtain a reasonable estimate. For example, the technique by Capra & Müller (1997) can be adapted to estimate µ(·). Specifically, consider that the time interval [0, τ ] is partitioned into L consecutive equidistant intervals: (t l−1 , t l ), with t 0 = 0 and l = 1, 2 . . . , L → ∞. Assume the smoothing parameter h such that h → 0 and n * h → ∞, as n * → ∞, where n * is the total number of observation time points. Coupled with additional conditions for the consistency in Capra & Müller (1997) , a smoothed
Here K(s) = (1 − s 2 )I(|s| ≤ 1). Other smoothers including higher-order kernel smoothers or local fitting with high-order polynomials can be also used under the necessary conditions of linearity, consistency and consistency with needed rate in Capra & Müller (1997) .
When β Q = 0, the parameter θ is not identified in the model (4). As in Davies (1977 Davies ( , 1987 , θ cannot be estimated under the null hypothesis and, subsequently, traditional large sample theory does not apply. If θ were known, however, we would only need to solve for
T in the reduced E(β, θ) = 0 of (7), e.g., the first p 1 equations with ψ(t) = Z(t).
is asymptotically χ 2 q -distribution with q = dim{Q(t)} under H 0 : β Q = 0 of no treatment efficacy, and larger S(θ) would lead to more evidence against H 0 as in Wei et al. (1990) .
Since θ is usually unknown, we consider the one-sided test statistic against H 1 : β Q > 0 as
where θ l and θ u are the lower and upper limits of the possible values of θ, respectively.
Following Davies (1987) , for some s ≥ 0, it is calculated that
In particular, when Q(·) is the treatment indicator of q = 1, an approximate significance pvalue given the observed S = S 0 can thus be calculated as pr(χ
where M is the piecewise numerical difference approximation of
For the θ ∈ Θ ⊂ R p 2 of higher dimension, i.e., p 2 > 1, a natural extension of S = sup θ∈Θ {S(θ)} can be used, although its theoretical calculation of significance probability bounds is foreseeably complicated. In practice, we can instead adapt a computerintensive resampling method by Parzen et al. (1994) for ease of calculation. Specifically, for a given set of n iid standard normal deviates, { 1 , 2 , . . . , n }, say, multiplying the individual terms in (7) as E(β, θ)
zero with the variance of Σ conditional on the observed data. Thus, n −1/2 E (β, θ) would have the same limiting distribution as n −1/2 E(β, θ). As a result, we would generate a large number of sets of { i }'s to calculate the empirical distribution of S = sup θ∈Θ S(θ) =
Then an approximate significance p-value is the proportion of S ≥ S 0 .
Examples
Distributions of bivariate action duration times
As proposed in §2.1, the bivariate action duration times can be modelled by the Gamma frailty model. To gain some concrete sense about this family of distributions and their ultimate impact on the mean response curve, we examine a few examples. One choice is to use the Weibull forms for λ U (·) and λ W (·), i.e., λ U ωt ω−1 and λ W ωt ω−1 , respectively, where ω is a parameter. Thus, the bivariate density function and survival function of (U, W ) becomes
This is the generalised Pareto power distribution, also called the bivariate Burr distribution.
When ω = 1, the marginal distributions of (U, W ) become exponential. The bivariate density and survival functions when λ U = λ W = ω = 1 and α = 0.5 are demonstrated in Fig. 1 .
[ Fig. 1 about here]
The impact of the inclusion of varying effectiveness duration on the mean response model is reflected in the shape of the function of H(t), as demonstrated in model (4). The function of H(t) under the mentioned distributions of (U, W ) are plotted in Fig. 2 under three λ W = 0.5, 1.0 and 1.5, which represent the relatively short/long length of the effectiveness durations. It is not surprising to see that all of the curves appear to be tied down toward t = 0 and t = ∞ with a peak in the middle. This mimics the phenomenon of effect erosion that is often observed, which is for the treatment to take effect gradually, reach peak efficacy and then dampen as time goes on. More interestingly, as λ W increases, the time period of action onset becomes shorter, and the curves appear to have uniformly lower efficacy, i.e., H(t; λ W = 1.5) ≤ H(t; λ W = 1.0) ≤ H(t; λ W = 0.5).
[ Fig. 2 about here]
Simulations
Moderate simulations are conducted mainly to demonstrate the validity of the estimation procedures. According to our models, there are three steps to simulating the data sets (1) according to a random effect Poisson process with intensity rate following Gamma (1,0.5).
The total time period of observation following uniform distribution with mean of 20 yields about 11 observation times per subject. (3) Repeated responses (y(t i1 ), y(t i2 ), . . . , y(t i,m i )):
the repeated responses are simulated according to the following model:
Here Q is the treatment indicator of a Bernoulli random variable with success probability of 50%, R(t) are standard normal, ε(t) is a Gaussian process with cov{ε(s), ε(t)} = exp(−|s−t|) and µ(t) = t 1/2 and sin(2πt), respectively. The true values of (β R , β Q ) are (1, 0), (−1, 0),
(1, 1) and (−1, 1), respectively. The simulation results are summarised in Table 1 . For each entry in the table, 1,000 replicates are simulated to estimate the bias and empirical coverage probability. The bias is defined as the difference between the sample mean of the estimates over the 1,000 replicated data sets and its true value. The empirical coverage probability is the percentage of Wald-type 95% confidence intervals that include the true parameters. It is evident that the estimators are virtually unbiased and the nominal confidence intervals carry reasonable coverages.
[ Table 1 about here]
A real randomised clinical trial
Between November 1997 and April 1999, a landmark randomised trial, HIVNET 012, was conducted to assess the safety and efficacy of single-dose nevirapine versus zidovudine for the prevention of mother-to-child HIV-1 vertical transmission among pregnant women in lessdeveloped countries (http://www.hptn.org/research studies/hivnet012.asp). In this trial, a total of 626 HIV-1 infected pregnant women in Uganda were recruited and randomly assigned to either nevirapine or zidovudine at more than 36 weeks' gestation. Complete medical histories and physical examinations of all participants were collected before their entry to the study, on enrolment, at delivery, at discharge from hospital, and at 7 days and 6 weeks after delivery. According to the trial protocol, the primary efficacy endpoint was the HIV-1 infection of neonates and HIV-1-free survival rates. By the end of this trial, the primary efficacy analysis showed that the HIV-1 transmission risk in the zidovudine and nevirapine groups was 10.4% and 8.2% at birth (p > 0.3); 21.3% and 11.9% by age 6-8 weeks (p < 0.003); and 25.1% and 13.1% by age 14-16 weeks (p < 0.001), respectively, which suggests that single-dose nevirapine could significantly lower the vertical HIV-1 transmission risk in less-developed countries significantly (Guay et al., 1999) .
One of the important secondary objectives of this trial specified in the protocol is to determine the relationship of maternal plasma RNA levels at the delivery with the rate of perinatal transmission. Therefore, it is critical to first focus on how the administration of nevirapine would affect the maternal viral load. In fact, quantitative plasma HIV-1 RNA measurements were taken repeatedly before entry, at delivery, and at 7 days and 6 weeks after delivery, respectively. These measurements can be used to compare the immunologic disease progression over time.
Unlike the control drug, zidovudine, nevirapine is a non-nucleoside benzodiazepine derivative. It does not have to be taken in by the human cell and metabolized to its active form and, thus, it generally takes effect against intracellular and extracellular virus immediately after administration (Zhang et al., 1996) . However, the administration of nevirapine in labor is not soon enough to cause a decrease in viral load in labor, and it is difficult to determine precisely at what time the nevirapine takes the immediate effect. On the other hand, the nevirapine was administered only once in order to maintain certain plasma drug concentration for up to seven days. Preliminary studies showed that the potent antiviral effect usually persists for one to two weeks, followed by a rapid development of viral resistance to nevirapine and an increase in plasma virus. By the fourth week after drug administration, usually all of the subjects would develop viral resistance. In Fig. 3 , the maternal plasma viral loads are plotted for both treatment arms. As shown in the figure, their mean functions do not vary dramatically at immediate administration or in the relative long-run after the fourth week. More smoothed lowess curves also show similar patterns.
[ Fig. 3 about here]
For demonstration purposes, we let Q(t) be the treatment indicator of nevirapine versus zidovudine and R(t) be the number of days since first dose of drug administration and maternal age, respectively, in the proposed model (3). The estimates of regression parameters and their estimated standard errors are tabulated in Table ( 2). In contrast, this table also
shows the usual generalized estimating equation estimates without considering the varying effectiveness durations. As shown in the table, the use of nevirapine significantly lowers the HIV RNA viral load in both methods. Specifically, when the varying durations were ignored, the generalised estimating equation estimates of HIV viral load reduction by the nevirapine was merely 0.0434 in log 10 , i.e., 10 0.434 = 2.7 times that of the zidovudine. The subject-specific reduction, however, shows a much larger magnitude of 1.379 in log 10 , i.e., 10 1.379 = 23.9 times when the varying treatment effectiveness durations are included in the mean response model. In fact, the latter estimate is quite consistent with the estimated reduction of 1.3 in log 10 that was reported in a phase I/II pharmacokinetic study of nevirapine (Musoke et al., 1999) .
[ Table 2 about here]
Extensions
In this section, we discuss some potential extensions of the proposed methods and the associated estimation procedures. To simplify our presentation, we assume that β Q = 0. As shown earlier, when β Q = 0, all the discussed extensions can accommodate the hypothesis testing of treatment efficacy by considering the test statistics similar to S.
Multiplicative mean response models
In addition to the additive model in (1), there is also a parallel multiplicative model proposed in the literature (Cheng & Wei, 2000) ,
to analyze the repeated measurements. The mean structure of this model is equivalent to those of the additive model when the response curves are properly transformed, for instance, if the Y (t) in model (9) is log-transformed. Nevertheless, the multiplicative model also assumes constant treatment effect and may not be appropriate in the presence of varying effectiveness durations, either. To include varying effectiveness durations, we propose the following model:
The marginalised version of this model is thus
Apparently, exp{β T Q Q i (t)}H(t) + {1 − H(t)}, which is the weighted average of exp{β T Q Q i (t)} and 1, would approach 1 as t goes to 0 or ∞. When Q i (·) is the treatment indicator, this property reflects the erosion phenomenon in the observed response curves. Unlike the additive model (4), however, the marginalised multiplicative model does not maintain the linear structure on β Q , which may add complexity in estimation.
To estimate the parameters (β, θ) in model (10), consider
are the zero-mean stochastic processes. The following estimating equations can thus be used
Again, denote ( β, θ) as the solutions to E ρ (β, θ) = 0. Then the similar techniques proposed earlier lead to the large-sample properties of consistency as well as asymptotic normality,
and
, respectively. Here, D ρ and Σ ρ can be estimated by their empirical counterparts respectively.
Covariate-dependent observation times
Usually in a well-designed randomised clinical trial, repeated measurements are supposed to be collected at a pre-determined or fixed set of time points to avoid potential bias or missing values in the data set. In reality, however, measurements may be actually observed at varying sets of time points for different individuals, and may be further affected by the subjects' covariates (Sun & Wei, 2000; Lin & Ying, 2001 ). In the statistical literature, when the mean functions of the counting processes are different, the following model is usually used,
where κ is a parameter and η(·) is an unspecified baseline function, as in Pepe & Cai (1993) and Lawless & Nadeau (1995) . Hence, the following estimating equations can be used to estimate κ,
with respect to κ. Let dΩ µ,η (t) = η(t)dΩ µ (t). Since
T * Z i (t)}dΩ µ,η (t), the following estimating equations can be similarly established for (β T , θ T , κ T ) T as in (7),
Then following the arguments in Sun & Wei (2000) , it is true that they are consist and have the asymptotic normality as,
Hence, by the normal approximation of (E 1 , E N ) as shown the Appendix, the asymptotic variance of (13) can be estimated by
where D N , D 1 and Σ 1 are their respective empirical estimates.
Isotonic regression of mean response models
In either the additive model (1) or the multiplicative model (9), the mean of the baseline response curves is assumed to be arbitrarily unspecified. In some randomised trials, for instance, the subjects' baseline mean response curves may have special monotonic shapes.
They can be either monotonically increasing or decreasing, depending upon the underlying measurement progression being persistently ameliorating or deteriorating. Therefore the marginal model (4) is extended as in
with µ(·) ∈ M, where M is the set of all the monotonically nonincreasing functions, or monotonically nondecreasing functions, denoted by M − or M + , respectively. Without loss of generality, we focus on M − in this section.
When there is no covariate information included in (14), the regression model reduces to a simple isotonic estimation problem. That is, we need to find µ(·) ∈ M − such that
with the norm · defined as in Rice & Silverman (1991) . Thus the computational algorithms, such as the most widely used Pooled Adjacent Violators Algorithm or the Minimum Lower Set Algorithm, can be used (Robertson et al., 1988) . When the covariate information is included as proposed in the model, we can adapt the back-fitting algorithm as in Zeger & Diggle (1994) to obtain the final estimates of the baseline function µ(·) and the parameters.
Algorithm.
1. Consider ( β [k] , θ [k] ) are obtained in the kth iterative step, k = 1, 2, . . ., where
Use one of the aforementioned algorithms to compute µ
In fact, the proposed isotonic regression model belongs to a more general additive isotonic model (Bacchetti, 1989) ,
where (µ 1 , µ 2 , . . . , µ P ) are the P -dimensional isotonic function vectors. When there is no covariate information involved, the backfitting algorithm by Hastie & Tibshirani (1990) can be used with the Pooled Adjacent Violators Algorithm to individual µ i iteratively. When the covariate information is included, it is straightforward to further extend the above algorithm for the estimation in this model. To avoid complicated variance calculation of the estimators, computer-intensive methods, such as the bootstrap method (Efron & Tibshirani, 1994) , can be used.
As shown earlier, the marginalised model (4) do not need smoothing and may have more efficient estimation, for instance, the differencebased method by Yatchew (1997) for the partial linear models with less loss of efficiency, more future in the semiparametric model efficiency framework of Bickel et al. (1993) is needed.
Along with the efficiency calculation, the technical development of asymptotic theory for the smoothing baseline estimators in §2 and the isotonic regression algorithms in §3 will be addressed in separate manuscripts, given the interest in development of these theories beyond the scope of the current manuscript.
dW ( in the induced probability. The calculation of the variance-covariance matrix of Σ is straightforward.
A.2. Asymptotic variance of n
The asymptotic normality of the joint distribution of n −1/2 (E 1 (β * , θ * , κ * ) T , E N (κ * ) T ) T can be similarly established following the arguments in Lin & Wei (1989) and Sun & Wei (2000) .
To calculate its associated asymptotic variance, it is noted that n −1/2 E N (κ * ) = n and its empirical estimates as e i , respectively. Thus the variance-covariance matrix of n −1/2 (E 1 (β * , θ * , κ * ) T , E N (κ * ) T ) T can be approximated by
, where i = τ 0 ∆ i (t)Φ(t){ϕ i (t) − ϕ 1 (t)} exp{ κ T Z i (t)}d Ω µ,η (t) and (βQ*, βR*) = (1, 0) (βQ*, βR*) = (−1, 0) (βQ*, βR*) = (1, 1) (βQ*, βR*) = (−1, 1) 
